Related Experiment Videos
Antiplatelet agents and stroke prevention
1Stroke Journal, Indianapolis, IN 46202, USA.
Insights
Aspirin (acetylsalicylic acid) effectively prevents secondary strokes. Higher doses may offer enhanced benefits, though evidence is limited, and it serves as an alternative to warfarin for atrial fibrillation patients.
Area of Science:
- Neurology
- Pharmacology
- Cardiovascular Medicine
Background:
- Aspirin (acetylsalicylic acid, ASA) is a cornerstone in secondary stroke prevention.
- Optimal dosing strategies for ASA in stroke prevention remain an area of investigation.
Purpose of the Study:
- To review the efficacy of aspirin (ASA) in secondary stroke prevention.
- To evaluate the role of different ASA dosages and combination therapies.
Main Methods:
- Literature review of studies on aspirin, ticlopidine, clopidogrel, dipyridamole, and warfarin in stroke prevention.
- Analysis of evidence regarding ASA dosage and its impact on stroke risk reduction.
Main Results:
- ASA (75-1300 mg/day) is effective for secondary stroke prevention.
- Higher ASA doses may enhance efficacy, but robust evidence is lacking.
- Clopidogrel and ticlopidine show comparable or superior efficacy to certain ASA doses.
- Adding dipyridamole to ASA has shown mixed results, with no clear benefit over higher-dose ASA alone.
- ASA is a viable alternative to warfarin for atrial fibrillation patients with contraindications.
Conclusions:
- Aspirin remains a primary choice for secondary stroke prevention, with potential benefits from higher doses.
- Combination therapies require further investigation, as higher-dose ASA alone may suffice.
- ASA is recommended for specific patient groups, but not for low-risk asymptomatic elderly individuals without further study.
Abstract:
Aspirin (acetylsalicylic acid [ASA]) from 75 to 1,300 mg/day is an effective agent in the secondary prevention of stroke. Although no properly designed study has been performed, circumstantial evidence suggests that the favorable effect of ASA for stroke may be enhanced by higher doses. Ticlopidine is more effective than 1,300 mg/day of ASA, and clopidogrel is at least as effective as 325 mg of ASA a day; but, for various reasons, ASA at higher doses is still first choice by many. Three studies have shown no benefit of adding dipyridamole to ASA. A fourth did, but, in addition to other problems, the results are no better than those obtained by higher doses of ASA alone. ASA is an effective alternate to warfarin for patients with atrial fibrillation and contraindications to warfarin. Until a proper study has been performed, ASA is not recommended for the prevention of stroke in a low-risk asymptomatic elderly population.